Volume 14, Number 9—September 2008
Pediatric Parapneumonic Empyema, Spain
|Age, mo, mean ± SD (range)||51.8 ± 31 (2–180)|
|Gender ratio, M/F||1.06|
|Underlying disease, %†||4|
|Oral antimicrobial drugs before admission, %‡||29|
|Antimicrobial drug free before thoracocentesis, %§||23|
|PCV7 >1 dose, %||31|
*PPE, pediatric parapneumonic empyema; PCV7, 7-valent pneumococcal conjugate vaccine.
†Underlying disease included (no. patients): lymphoma (2), congenital heart disease (2), mild psychomotor retardation (2), varicella zoster infection (2) and genetic disease (1).
‡Median duration: 3 d, range 1–17 d.
§100/147 children who had not been treated with oral antimicrobial drug therapy before admission received intravenous antimicrobial drug treatment before thoracocentesis for a median of 2 d (range 1–10 d).
- Page created: July 13, 2010
- Page last updated: July 13, 2010
- Page last reviewed: July 13, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)